The COVID-19 pandemic in 2020 quickly changed how clinical trials are conducted. Many companies suddenly needed to switch to decentralized trial models to protect their studies and the safety of participants. Now the main question being asked is where do clinical trials go from here and what can we expect in 2021? And what does the future hold for emerging technologies, virtual trials, and patient centricity in the age of COVID?
In this webinar segment, Michelle Longmire of Medable and Jeff Kasher of Patients Can’t Wait discuss how a decentralized clinical trial model might enable greater patient diversity in studies. Debbie Profit of Otsuka also looks at how companies should prepare for onsite FDA inspections during COVID.